- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07939490
JULÄINE™ - Neck Skin Laxity Clinical Investigation
A Prospective, Multi-Centre, Single-Arm, Open-Label Pivotal Clinical Investigation to Evaluate the Safety and Clinical Performance of JULÄINE™ in Adults With Neck Skin Laxity
This study will assess the safety of JULÄINE™, an injectable filler containing poly-L-lactic acid (PLLA), and whether it can improve loose skin on the neck.
The main question is whether more than 60% of treated participants show an improvement of at least one level on a neck skin laxity scale, 26 weeks after their final treatment. Improvement will be measured by comparing neck skin looseness before and after treatment.
The study plans to enroll adults aged 18 years or older with mild to moderately severe loose neck skin at three sites. All participants will receive the filler during three treatment sessions, approximately four weeks apart.
Participation will last approximately 14 months, including screening, treatment, and follow-up until 52 weeks after the final treatment. Investigators will assess changes using standardised photographs, measurements of skin elasticity, and questionnaires about participants' views of their neck appearance. The study will also monitor adverse events through the final follow-up visit.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Karina Caramico
- Phone Number: (+46) 76 336 39 48
- Email: k.caramico@nordbergmedical.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 years or older with mild to moderate-to-severe neck skin laxity (Grade 2-4 on Neck Laxity Scale).
- Willing to avoid aesthetic procedures involving the neck and lower face and changes to treatments affecting skin quality during the study.
- If of childbearing potential, a negative pregnancy test and agreement to use highly effective contraception throughout treatment and for eight weeks afterward.
- Able to provide written informed consent and comply with study visits, assessments, and post-treatment instructions.
Exclusion Criteria:
- Pregnancy, breastfeeding, or planned pregnancy or reproductive donation/retrieval procedures during the study or within eight weeks after the final visit.
- Previous neck surgery or major maxillofacial/cervical surgery; neck injections within 12 months; neck resurfacing or other aesthetic procedures within six months; or planned procedures during the study.
- Significant neck skin disease, infection, scarring, pigmentation abnormalities, or other conditions interfering with treatment or assessment.
- Prominent neck muscle bands, excessive facial or neck fat, or anatomy unsuitable for injectable treatment, as assessed by the investigator.
- Significant thyroid enlargement, uncontrolled thyroid disease, or other unstable endocrine disease.
- Allergy to device components, coagulation disorders, or anticoagulant/antiplatelet treatment, subject to protocol-defined exceptions.
- Recent immune-modifying treatment, chemotherapy, or systemic corticosteroids above 10 mg prednisone-equivalent daily; relevant corticosteroid/retinoid use; or treatments affecting collagen production.
- Hormone replacement therapy or thyroid medication that does not meet protocol-defined stability requirements.
- Immune deficiency, autoimmune disease, impaired wound healing, or significant malignant, dermatological, or systemic disease.
- Significant recent or expected weight changes, recent bariatric surgery, ongoing postoperative weight loss, or active weight-loss treatment, subject to protocol-defined exceptions.
- Any condition preventing valid informed consent or compliance with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: JULÄINE™
|
JULÄINE™, a poly-L-lactic acid (PLLA)-based injectable filler, administered beneath the skin on both sides of the neck during three treatment sessions, approximately four weeks apart. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Improved Neck Skin Laxity
Time Frame: Baseline and 26 weeks after the final treatment session
|
Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement. |
Baseline and 26 weeks after the final treatment session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Improved Neck Skin Laxity at 12 and 52 Weeks
Time Frame: Baseline and 12 and 52 weeks after the final treatment session
|
Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement. |
Baseline and 12 and 52 weeks after the final treatment session
|
|
Percentage of Participants With Improved Neck Skin Elasticity
Time Frame: Baseline and 26 weeks after the final treatment session
|
Percentage of participants showing an increase of at least 10% from baseline in the Cutometer R2 parameter, a measure of overall skin elasticity. Higher R2 values indicate greater elasticity. |
Baseline and 26 weeks after the final treatment session
|
|
Investigator-Rated Change in Neck Appearance
Time Frame: 12, 26, and 52 weeks after the final treatment session
|
Distribution of investigator ratings on the seven-point Global Aesthetic Improvement Scale, ranging from "very much improved" to "very much worse," based on comparisons of standardised post-treatment and baseline photographs. |
12, 26, and 52 weeks after the final treatment session
|
|
Change From Baseline in FACE-Q Appraisal of the Neck Score
Time Frame: Baseline and 12, 26, and 52 weeks after the final treatment session.
|
Change from baseline in participants' assessment of their neck appearance using the FACE-Q Appraisal of the Neck questionnaire. Raw scores are converted to a score ranging from 0 to 100 using the instrument's scoring algorithm. |
Baseline and 12, 26, and 52 weeks after the final treatment session.
|
|
Change From Baseline in Neck Skin Firmness and Elasticity Measured by Cutometer
Time Frame: Baseline and 12, 26, and 52 weeks after the final treatment session.
|
Change from baseline in four Cutometer parameters: R0 (skin firmness), R2 (gross elasticity), R5 (net elasticity), and R7 (biological elasticity). Lower R0 values indicate firmer skin, while higher R2, R5, and R7 values indicate greater elasticity. |
Baseline and 12, 26, and 52 weeks after the final treatment session.
|
|
Incidence of Adverse Events and Device Deficiencies
Time Frame: From the first treatment through 52 weeks after the final treatment session
|
Number and percentage of participants experiencing adverse events, including device-related events, serious events, and unanticipated serious device-related events. Events will be characterised by type, severity, seriousness, and relationship to the device or injection procedure. Device deficiencies will be summarised separately. |
From the first treatment through 52 weeks after the final treatment session
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NB 15-TF-EU-100-38F
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.